Bio-Techne Unveils Five AI-Engineered Heat-Stable Growth Factors, Hyperactive Cytokines
TECH•Bio-Techne launched five new AI-engineered proteins—FGF-4, FGF-7 and FGF-8b heat-stable growth factors plus IL-3 heat-stable and IL-15 hyperactive cytokines—to its R&D Systems portfolio, aiming to boost stability, activity and scalability in advanced cell culture and cell therapy workflows. Early adopters report enhanced cell expansion and lower manufacturing costs.
1. Portfolio Expansion Details
On July 8, 2026, Bio-Techne expanded its R&D Systems AI-Engineered Designer Protein portfolio with five new proteins: FGF-4, FGF-7 and FGF-8b heat-stable growth factors, IL-3 heat-stable cytokine and hyperactive IL-15, designed for advanced cell culture and therapeutic development workflows.
2. Performance Improvements
Each new protein offers enhanced heat stability, increased activity and improved solubility, with early adopters reporting measurable gains in tumor-infiltrating lymphocyte expansion and operational efficiencies that reduce costs in cell therapy production.
3. Strategic Implications
This expansion reinforces Bio-Techne’s strategy to deliver next-generation signaling molecules that enhance reproducibility and scalability across discovery, development and commercial manufacturing, addressing critical challenges in scaling cell therapies from research to market.
